Suzuki H, Saruta T, Ferrario C M, Brosnihan K B
Jpn Heart J. 1987 May;28(3):413-26. doi: 10.1536/ihj.28.413.
The neurohormonal contribution to high blood pressure was investigated in 9 conscious two-kidney, two-clip Goldblatt (2K2C) hypertensive dogs during evolution of the benign and malignant phases after application of bilateral renal clips (BRC). Serial measurements were taken of the plasma renin activity (PRA), plasma angiotensin I-immunoreactivity (Ang I-ir), plasma angiotensin II-ir (Ang II-ir), renin substrate (RS) catecholamines [epinephrine (Epi) and norepinephrine (NE)] and vasopressin (AVP). Immediately after BRC, the elevation of the blood pressure (86 +/- 3 to 110 +/- 3 mmHg, p less than 0.01) was associated with an increase in heart rate (93 +/- 3 to 114 +/- 9 beats/min, p less than 0.01). These hemodynamic changes were accompanied by increases in PRA, Ang I-ir, Ang II-ir, Epi, NE and AVP. The renin angiotensin system was activated throughout the 3 week period following BRC, as indicated by increases in PRA, Ang I-ir and Ang II-ir. Catecholamines were elevated immediately after BRC, followed by a return toward the control values. AVP underwent a slight but not significant elevation after BRC, which was sustained during the 3 weeks. Production of malignant hypertension was affected by occlusion of one of the adjustable renal clips 3 weeks after BRC. A marked elevation of the blood pressure was associated with significant increases in PRA, Ang I-ir, Ang II-ir, Epi, NE and AVP, compared with the pre-occlusion values. In addition, pharmacologic experiments were performed in 6 of 9 dogs. Administration of angiotensin I converting enzyme inhibitor (SQ 14225) reduced the blood pressure both in the benign and malignant phases of 2K2C renovascular hypertension, and a ganglionic blocking agent (hexamethonium) also decreased the blood pressure. However, a specific, vascular acting AVP antagonist failed to reduce the blood pressure significantly. From this study, it seems likely that severe renal ischemia caused by renal clipping caused the activation of the renin-angiotensin and the sympathetic nervous system and elevation of serum vasopressin. However, there are no apparent differences between the benign and malignant phases of renovascular hypertension, except for the marked elevation of neurohormone levels in malignant hypertension.
在9只清醒的双肾双夹Goldblatt(2K2C)高血压犬中,研究了神经激素对高血压的影响。这些犬在双侧肾动脉夹闭(BRC)后经历了良性和恶性阶段的演变。连续测量血浆肾素活性(PRA)、血浆血管紧张素I免疫反应性(Ang I-ir)、血浆血管紧张素II免疫反应性(Ang II-ir)、肾素底物(RS)、儿茶酚胺[肾上腺素(Epi)和去甲肾上腺素(NE)]以及血管加压素(AVP)。BRC后立即出现的血压升高(从86±3 mmHg升至110±3 mmHg,p<0.01)与心率增加(从93±3次/分钟升至114±9次/分钟,p<0.01)相关。这些血流动力学变化伴随着PRA、Ang I-ir、Ang II-ir、Epi、NE和AVP的增加。BRC后的3周内,肾素-血管紧张素系统一直处于激活状态,表现为PRA、Ang I-ir和Ang II-ir升高。儿茶酚胺在BRC后立即升高,随后恢复至对照值。BRC后AVP有轻微但不显著的升高,并在3周内持续存在。BRC后3周,通过闭塞一个可调节肾动脉夹来诱导恶性高血压。与夹闭前相比,血压显著升高,同时PRA、Ang I-ir、Ang II-ir、Epi、NE和AVP也显著增加。此外,对9只犬中的6只进行了药理实验。给予血管紧张素I转换酶抑制剂(SQ 14225)可降低2K2C肾血管性高血压良性和恶性阶段的血压,神经节阻断剂(六甲铵)也可降低血压。然而,一种特异性的、作用于血管的AVP拮抗剂未能显著降低血压。从这项研究来看,肾动脉夹闭导致的严重肾缺血似乎激活了肾素-血管紧张素系统和交感神经系统,并使血清血管加压素升高。然而,肾血管性高血压的良性和恶性阶段之间没有明显差异,只是恶性高血压中神经激素水平显著升高。